New drug duo aims to fight Hard-to-Treat head and neck cancer
NCT ID NCT05054439
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This phase II trial tests a new drug called SI-B001 combined with the chemotherapy paclitaxel in 42 adults with recurrent or metastatic head and neck squamous cell carcinoma that has worsened after prior treatments. The goal is to see if the combination is safe and can shrink tumors. The study is active but no longer recruiting participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
Shanghai Oriental Hospital
Shanghai, Shanghai Municipality, 200120, China
-
The Affiliated Cancer Hospital of Guizhou Medical University
Guiyang, Guizhou, China
-
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
-
Union Hospital Tongji Medical College， Huazhong University of Science and Technology
Wuhan, Hubei, China
-
West China Hospital，Sichuan University
Chengdu, Sichuan, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SI-B001 (a targeted drug) combined with paclitaxel (a chemotherapy drug)
What this could lead to
If successful, this combination could offer a new treatment option for patients with advanced head and neck cancer that has stopped responding to standard therapies.
What could go wrong
This is a small, early-phase (Phase II) trial with only 42 participants. The combination may not prove effective or could cause significant side effects. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.